CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Status:
Recruiting
Trial end date:
2037-08-01
Target enrollment:
Participant gender:
Summary
This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating
relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study
participants and the immune T cells will be separated. T cells will be genetically modified
in a laboratory at UNC-Chapel Hill to enable them to produce CD30 antibody. The modified T
cells, called ATLCAR.CD30, will be able to target and attach to lymphoma cancer cells that
carry the CD30 antigen. Once they are attached, the T cells will attack and destroy the
lymphoma cancer cells. To prepare the body for the ATLCAR.CD30 cells, participants will
complete lymphodepletion with two chemotherapy agents. Lymphodepletion will happen over three
days prior to ATLCAR.CD30 infusion. If participants respond to this treatment, and there are
sufficient unused ATLCAR.CD 30 cells, they may be eligible to receive a second infusion. The
second infusion will be given after a second lymphodepletion chemotherapy. Most of the clinic
visits in this research will last between 1-8 hours.
Participants will be followed closely for 4 consecutive weeks after ATLCAR.CD30 infusion(s).
Other follow-up visits will happen on Weeks 6 and 8, and continue every 3 months for the
first year after infusion. Long-term follow up will continue annually for up to 15 years
after the last ATLCAR.CD30 infusion.
There are risks associated in participating in this research study. Risks of treatment
include pain, fever, nausea, vomiting, and neurotoxicity. Other risks are associated with
study procedures, such as biopsies, imaging, infusion, and breach of confidentiality.